People: Isis Pharmaceuticals Inc (ISIS.O)

ISIS.O on Nasdaq

45.88USD
30 Oct 2014
Price Change (% chg)

$0.87 (+1.93%)
Prev Close
$45.01
Open
$44.96
Day's High
$46.40
Day's Low
$44.56
Volume
2,083,170
Avg. Vol
2,127,421
52-wk High
$62.66
52-wk Low
$22.25

Search Stocks

Summary

Name Age Since Current Position

Stanley Crooke

69 1991 Chairman of the Board, President, Chief Executive Officer

Elizabeth Hougen

52 2013 Chief Financial Officer, Senior Vice President - Finance

B. Lynne Parshall

59 2013 Chief Operating Officer, Corporate Secretary, Director

Patrick O'Neil

40 2013 Senior Vice President - Legal, General Counsel

C. Frank Bennett

57 2006 Senior Vice President - Antisense Research

Richard Geary

56 2008 Senior Vice President - Development

Brett Monia

52 2012 Senior Vice President - Drug Discovery and Corporate Development

Joseph Loscalzo

62 2014 Director

Spencer Berthelsen

62 2002 Independent Director

Breaux Castleman

73 2013 Independent Director

Joseph Klein

53 2005 Independent Director

Frederick Muto

60 2001 Independent Director

Joseph Wender

69 1994 Independent Director

Wade Walke

Executive Director - Corporate Communications

Biographies

Name Description

Stanley Crooke

Dr. Stanley T. Crooke, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Isis Pharmaceuticals Inc. Dr. Crooke is a founder of Isis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Isis, from 1980 until January 1989, Dr. Crooke worked for SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.

Elizabeth Hougen

Ms. Elizabeth L. Hougen is Chief Financial Officer, Senior Vice President - Finance of Isis Pharmaceuticals, Inc. From January 2007 to December 2012, Ms. Hougen served as Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as Vice President, Finance. Prior to joining Isis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.

B. Lynne Parshall

Ms. B. Lynne Parshall, J.D., is Chief Operating Officer, Corporate Secretary, Director of Isis Pharmaceuticals Inc. She has been Chief Operating Officer since December 2007 and previously served as Chief Financial Officer from June 1994 through December 31, 2012. She also serves as Corporate Secretary, and has served with the Company in various executive roles since November 1991. Prior to joining Isis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Isis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American, California and San Diego bar associations. Ms. Parshall serves on the board of directors of Regulus Therapeutics, Inc. and Cytokinetcs Inc., two biopharmaceutical companies. Within the last five years, Ms. Parshall formerly served as a Director of CardioDynamics International Corporation and Corautus Genetics Inc., both biopharmaceutical companies.

Patrick O'Neil

Mr. Patrick R. O'Neil, Esq., is Senior Vice President - Legal, General Counsel of Isis Pharmaceuticals Inc., since January 2013. From September 2010 to January 2013, Mr. O’Neil served as Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within Legal department. Prior to joining Isis, Mr. O’Neil was an associate at Cooley LLP.

C. Frank Bennett

Dr. C. Frank Bennett, Ph.D., is Senior Vice President - Antisense Research of Isis Pharmaceuticals Inc., since January 2006. From June 1995 to January 2006, Dr. Bennett served as Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in Molecular and Cellular Biology department. Prior to joining Isis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore.

Richard Geary

Dr. Richard S. Geary, Ph.D., is Senior Vice President - Development of Isis Pharmaceuticals Inc., since August 16, 2008. From August 2003 to August 2008, Dr. Geary served as Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Isis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.

Brett Monia

Dr. Brett P. Monia, Ph.D. is the Senior Vice President - Drug Discovery and Corporate Development of Isis Pharmaceuticals Inc., since January 2012. From February 2009 to January 2012, Dr. Monia served as Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009, he served as Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within Molecular Pharmacology department.

Joseph Loscalzo

Dr. Joseph Loscalzo, M.D., Ph.D., is a Director of Isis Pharmaceuticals Inc. Dr. Joseph Loscalzo is currently serving as the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Post-training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005.

Spencer Berthelsen

Dr. Spencer R. Berthelsen, M.D., is an Independent Director of Isis Pharmaceuticals Inc., since May 2002. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 370 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He has been Chairman of their Board of Directors since October 2001. He has served as a Clinical Professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005.

Breaux Castleman

Mr. Breaux B. Castleman is Independent Director of Isis Pharmaceuticals, Inc. Since August 2001, Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a health care investment company, which recently sold its operations as a service provider of integrated care management and disease management. Mr. Castleman has been a director of USMD Holdings, Inc., a physician-led integrated healthcare system, since September 2009 and was a director of MELA Sciences, Inc., a medical device company, from 2003 until 2011.

Joseph Klein

Mr. Joseph Klein, III, is an Independent Director of Isis Pharmaceuticals Inc., since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities. Within the last five years, Mr. Klein formerly served on the board of directors of five publicly held biotechnology companies: BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. and Savient Pharmaceuticals, Inc.

Frederick Muto

Mr. Frederick T. Muto, J.D., is an Independent Director of Isis Pharmaceuticals Inc., since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Isis, in 1980 and became a partner in 1986. He is Chair of the firm’s Business Department and a founding partner of Cooley LLP’s San Diego office.

Joseph Wender

Mr. Joseph H. Wender is an Independent Director of Isis Pharmaceuticals Inc., since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he has been a Senior Consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is a managing partner and owns, with his wife, Colgin Cellars. As of March 2014, Mr. Wender is a director of CBS Outdoors America Inc., lessors of advertising space on out-of-home advertising structures.

Wade Walke

Basic Compensation

Options Compensation

Search Stocks